Related and Nonrelated Parties [Axis]
Related Party [Member]
Nonrelated Party [Member]
Equity Components [Axis]
Common Stock [Member]
Preferred Stock [Member]
Additional Paid-in Capital [Member]
Retained Earnings [Member]
Consolidated Entities [Axis]
Parent Company [Member]
Pharmalectin, Inc. [Member]
Business Combination [Axis]
NDPD Pharma Inc [Member]
Ownership [Axis]
Pharmalectin (BVI), Inc. [Member]
Investment, Name [Axis]
Pharmalectin India Pvt Ltd [Member]
Debt Instrument [Axis]
Promissory Notes [Member]
Debt Conversion Description [Axis]
2021 Note [Member]
Warrant [Member]
Class of Stock [Axis]
Convertible Preferred Stock [Member]
Title and Position [Axis]
David Platt [Member]
Affiliate [Member]
Chief Financial Officer [Member]
Chief Executive Officer [Member]
Director [Member]
Affiliated Entity [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Axis]
Four Securities Purchase Agreements [Member]
Short-Term Debt, Type [Axis]
Convertible Notes Payable [Member]
2021 Notes [Member]
Three Notes [Member]
Note Sold in Exchange for Cash [Member]
Award Type [Axis]
Market Closing of Common Stock [Member]
Statistical Measurement [Axis]
Minimum [Member]
Sale of Stock [Axis]
Private Placement [Member]
Subsequent Event Type [Axis]
Subsequent Event [Member]
Measurement Input Type [Axis]
Measurement Input, Price Volatility [Member]
Measurement Input, Expected Term [Member]
Measurement Input, Risk Free Interest Rate [Member]
Measurement Input, Expected Dividend Rate [Member]
Preferred Stock Issued and Outstanding [Member]
Stock Conversion [Member]
Payroll Forfeiture [Member]
2021 Stock Plan [Member]
Common Stock Issued and Outstanding [Member]
Stock Plan 2021 [Member]
Warrants [Member]
Consulting Fees [Member]
Common Stock Issued [Member]
Commision [Member]
Maximum [Member]
Warrant One [Member]
Warrant Two [Member]
Warrant Three [Member]
Plan Name [Axis]
2021 Stock Plan [Member]
Share-Based Payment Arrangement, Option [Member]
Deferred Bonus and Profit Sharing Arrangements, Individual Contracts, Type of Deferred Compensation [Axis]
Stipend [Member]
Bonus [Member]
Performance Grant [Member]
Employment Agreements [Member]
Unit Offering [Member]
Plan 2021 [Member]
Plan 2021 One [Member]
Consulting Fee [Member]
Commission [Member]
Private Placement One [Member]
Consulting Fee One [Member]
Consulting Fee Two [Member]
Cover [Abstract]
Document Type
Amendment Flag
Amendment Description
Document Registration Statement
Document Annual Report
Document Quarterly Report
Document Transition Report
Document Shell Company Report
Document Shell Company Event Date
Document Period Start Date
Document Period End Date
Document Fiscal Period Focus
Document Fiscal Year Focus
Current Fiscal Year End Date
Entity File Number
Entity Registrant Name
Entity Central Index Key
Entity Primary SIC Number
Entity Tax Identification Number
Entity Incorporation, State or Country Code
Entity Address, Address Line One
Entity Address, Address Line Two
Entity Address, Address Line Three
Entity Address, City or Town
Entity Address, State or Province
Entity Address, Country
Entity Address, Postal Zip Code
Country Region
City Area Code
Local Phone Number
Extension
Written Communications
Soliciting Material
Pre-commencement Tender Offer
Pre-commencement Issuer Tender Offer
Title of 12(b) Security
No Trading Symbol Flag
Trading Symbol
Security Exchange Name
Title of 12(g) Security
Security Reporting Obligation
Annual Information Form
Audited Annual Financial Statements
Entity Well-known Seasoned Issuer
Entity Voluntary Filers
Entity Current Reporting Status
Entity Interactive Data Current
Entity Filer Category
Entity Small Business
Entity Emerging Growth Company
Elected Not To Use the Extended Transition Period
Document Accounting Standard
Other Reporting Standard Item Number
Entity Shell Company
Entity Public Float
Entity Bankruptcy Proceedings, Reporting Current
Entity Common Stock, Shares Outstanding
Documents Incorporated by Reference [Text Block]
Defined Benefit Plan [Table]
Defined Benefit Plan Disclosure [Line Items]
ASSETS
Current assets:
Cash
Pre-payment
Total current assets
Intangibles, net
Total assets
LIABILITIES AND STOCKHOLDERS’ DEFICIT
Current liabilities:
Accounts payable and accrued expenses
Accounts payable affiliates
Un-issued shares liability
Loan from affiliates
Other short-term loans
Derivative Liability
Convertible notes payable, net of premium and discount
Total current liabilities
Total liabilities
Commitments and contingencies
Stockholders’ deficit:
Preferred stock, $0.001 par value; 50,000,000 shares authorized, 43,283,991 issued and outstanding as at June 30, 2026, and December 31, 2025
Common stock, $0.001 par value; 400,000,000 shares authorized; 114,695,220 and 108,147,731 issued and outstanding as at June 30, 2026, and December 31, 2025, respectively
Additional paid-in capital
Accumulated deficit
Total stockholders’ deficit
Total liabilities and stockholders’ equity
Statement of Financial Position [Abstract]
Preferred stock, par value
Preferred stock, shares authorized
Preferred stock, shares issued
Preferred stock, shares outstanding
Common stock, par value
Common stock, shares authorized
Common stock, shares issued
Common stock, shares outstanding
Income Statement [Abstract]
Operating expenses:
Research and development
General and administrative
General and administrative affiliates
Total operating expenses
Loss from operations
Other expenses:
Change in fair value (“FV”) of derivative
Interest expense
Interest expense affiliates
Amortization of IP
Total other income (expenses)
Net income (loss) before provision for income taxes
Provision for income taxes
NET INCOME (LOSS)
Net loss attributable to the non-controlling interest
NET INCOME (LOSS) ATTRIBUTABLE TO BIOXYTRAN
Earnings per Common share, basic
Earnings per Common share, diluted
Weighted average number of Common shares out-standing, basic
Weighted average number of Common shares out-standing, diluted
Statement [Table]
Statement [Line Items]
Balance
Balance, shares
Shares issued under the 2021 Plan affiliates
Shares issued under the 2021 Plan affiliates, shares
Shares issued under the 2021 Plan
Shares issued under the 2021 Plan, shares
Stock class conversion
Stock class conversion, shares
Prior year accrued payroll forfeiture by Mgmnt
Net loss
Cash stock transactions
Cash stock transactions, shares
Issuance to consultants
Issuance to consultants, shares
Issuance of warrants
Balance
Balance, shares
Statement of Stockholders' Equity [Abstract]
Forfeiting payroll taxes
Statement of Cash Flows [Abstract]
CASH FLOWS FROM OPERATING ACTIVITIES:
Adjustments to reconcile net loss to net cash used in operating activities:
Amortization of IP
Stock-based compensation
Stock-based compensation affiliates
Change in FV of Derivative
Changes in operating assets and liabilities:
Change in pre-paid expenses
Accounts payable and accrued expenses
Accounts payable and accrued expenses affiliates
Net cash used in operating activities
CASH FLOWS FROM INVESTING ACTIVITIES:
Investment in intangibles
Net cash used in investing activities
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from stock sales
Proceeds from warrant issuance
Short-term loans
Short-term loans from affiliates
Net cash provided by financing activities
Net decrease in cash
Cash, beginning of period
Cash, end of period
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION
Interest paid
Income taxes paid
NON-CASH INVESTING & FINANCING ACTIVITIES
Payroll forgiveness affiliates
Organization, Consolidation and Presentation of Financial Statements [Abstract]
BACKGROUND AND ORGANIZATION
Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
GOING CONCERN AND MANAGEMENT’S LIQUIDITY PLANS
Segment Reporting [Abstract]
SINGLE SEGMENT DISCLOSURE
Related Party Transactions [Abstract]
AFFILIATES TRANSACTIONS
Intangible Asset, Goodwill and Other [Abstract]
INTANGIBLES
Payables and Accruals [Abstract]
ACCOUNTS PAYABLES AND ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES
Debt Disclosure [Abstract]
CONVERTIBLE NOTES PAYABLE
Convertible Note And Embedded Derivative
CONVERTIBLE NOTE AND EMBEDDED DERIVATIVE
Allocation Of Fair Value In Private Placement
ALLOCATION OF FAIR VALUE IN PRIVATE PLACEMENT
Equity [Abstract]
STOCKHOLDERS’ EQUITY
Share-Based Payment Arrangement [Abstract]
STOCK OPTION PLAN AND STOCK-BASED COMPENSATION
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES
Subsequent Events [Abstract]
SUBSEQUENT EVENTS
Cash
Use of Estimates
Net Loss per Common Share, basic and diluted
Stock Based Compensation
Research and Development
Intangibles – Goodwill and Other
Accrued Expenses
Reclassification
Convertible Debt
Embedded Derivatives
Warrants
Fair Value
Recent Accounting Pronouncements
SCHEDULE OF INTANGIBLES
SCHEDULE OF ACCOUNTS PAYABLES AND ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES
SCHEDULE OF OUTSTANDING CONVERTIBLE NOTES
SCHEDULE OF FAIR VALUE MEASUREMENT OF EMBEDDED DERIVATIVE
SCHEDULE OF ALLOCATION OF FAIR VALUE IN PRIVATE PLACEMENT
SCHEDULE OF SIGNIFICANT INPUTS OF FAIR VALUE MEASUREMENT
SUMMARY OF WARRANT ACTIVITY
Accumulated Other Comprehensive Income (Loss) [Table]
Accumulated Other Comprehensive Income (Loss) [Line Items]
SCHEDULE OF PREFERRED STOCK ISSUED AND OUTSTANDING
SCHEDULE OF COMMON STOCK ISSUED AND OUTSTANDING
SCHEDULE OF STOCK WARRANTS VALUATION ASSUMPTIONS
SCHEDULE OF COMMON STOCK WARRANT ACTIVITY
SCHEDULE OF WARRANT OUTSTANDING AND EXERCISABLE WARRANTS
SCHEDULE OF GRANTED AND ISSUED STOCK AWARDS
Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
SCHEDULE OF SHARES AWARDED
Consolidation, Less-than-Wholly-Owned Subsidiary, Parent Ownership Interest, Effect of Change [Table]
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]
Common stock par value
Common stock acquired percentage
Outstanding shares held
Outstanding shares percentage
Short-Term Debt [Table]
Short-Term Debt [Line Items]
Cash FDIC insured amount
Share Price
Debt Conversion, Converted Instrument, Shares Issued
Class of Warrant or Right, Outstanding
Shares of Common Stock due for issuance
Common shares issued for the conversion of principal and accrued interest
Debt Conversion, Description
Research and development expenses
Discount to market price rate
OrganizationConsolidationAndPresentationOfFinancialStatementsTable [Table]
OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems [Line Items]
Cash
Working capital
Accumulated deficit
Proceeds from private placement
Affiliates short term loans
Short term loan
Related Party Transaction [Table]
Related Party Transaction [Line Items]
Number of shares granted
License amounts
Capitalized patent costs
Estimated Remaining Life (years)
Accumulated amortization
Intangible assets, net
Impairment charges of intangibles
Affiliate liabilities
Pension/401K
Payroll tax reserve
Accounts payable affiliates
Professional fees
Other accounts payable
Interest
Un-issued shares
Short term loan
Convertible note payable
Derivative liability
ScheduleOfAccountsPayableAndAccruedExpensesAndOtherCurrentLiabilitiesTable [Table]
ScheduleOfAccountsPayableAndAccruedExpensesAndOtherCurrentLiabilitiesLineItems [Line Items]
Accrued liabilities
Compensation claims
Stock issued during period value conversion of convertible securities
Loam amount
Interest rate
Accrued interest
Accounts payable to related parties
Short term loans
Accrued interest
Total principal due
Total accrued interest
Total amount due
Face value
Debt discount
Aggregate principal amount
Interest rate
Note conversion description
Default Interest rate
Prepayment percentage
Notes extended date
Debt discount
Conversion Price
ConvertibleNoteAndEmbeddedDerivativeTable [Table]
Debt conversion price
Reset price
Debt maturity date
Current market price of common stock
Debt conversion price
Conversion price will be reduced by percentage
Adjustment Multiplier
Estimated fair value of derivative
Volatility impact description
Description of price risk exposure
Concentration risk description
Schedule Of Fair Value Measurement Of Embedded Derivative
Current Stock Price
Volatility
Risk-Free Rate
Subsidiary or Equity Method Investee, Sale of Stock, Type [Table]
Subsidiary, Sale of Stock [Line Items]
Fair value of common stock
% of Total Fair Value, Common stock
Allocation of Proceeds Common Stock
Share price
Fair value of warrants
% of Total Fair Value, Warrants
Allocation of Proceeds Warrants
Allocation per Share/Warrant
Standalone fair value
% of Total Fair Value
Allocation of Proceeds
Number of shares issued
Business Combination [Table]
Business Combination [Line Items]
Warrants, measurement input
Warrants, expected term
Class of Warrant or Right [Table]
Class of Warrant or Right [Line Items]
Number of Warrants Outstanding, beginning of year
Weighted Average Exercise Price, Outstanding, beginning of year
Weighted average remaining expected term, outstanding
Number of Warrants, Granted
Weighted Average Exercise Price, Granted
Weighted average remaining expected term, granted
Number of Warrants, Exercised
Weighted Average Exercise Price, Exercised
Number of Warrants, Forfeited/Cancelled
Weighted Average Exercise Price, Forfeited/Cancelled
Number of Warrants Outstanding, end of year
Weighted Average Exercise Price, Outstanding, end of year
Share price
Proceeds from issuance of warrants
Warrants and rights outstanding
Sale of stock
Bonus shares
Net cash proceeds
Payments for commission
Allocation calculation description
Warrants exercise price
Warrant expire date description
Warrants outstanding
Number of shares issued upon exericse of warrants
Warrant exercise date
Shares
Amount
Accrued payroll
Private placement offering
Broker commission
Warrants outstanding, number of warrants
Weighted average remaining contractual term, Ending balance
Weighted average exercise price
Private placement offering
Cash commission
Risk-free interest rate
Expected dividend yield
Volatility factor (monthly)
Expected life of warrant
Weighted Average Exercise Price, Balance
Weighted average remaining contractual term, Beginning balance
Weighted Average Exercise Price, Granted
Weighted Average Exercise Price, Exercised
Weighted Average Exercise Price, Forfeited/Canceled
Weighted Average Exercise Price, Balance
Weighted- Average Remaining Expected Term, Granted
Warrants Outstanding, Exercise Price
Warrants Outstanding, Number of Warrants
Warrants Outstanding, Weighted Average Exercise Price Per Share
Warrants Outstanding, Weighted Average Remaining Contractual Life (Years)
Warrants Outstanding, Aggregate Intrinsic Value
Weighted average exercise price
Warrants exercisable, weighted average remaining contractual life
Warrants outstanding, aggregate intrinsic value
GrantedAndIssuedStockAwardsTable [Table]
GrantedAndIssuedStockAwardsLineItems [Line Items]
Preferred shares
Preferred stock, convertible, terms
Stock awards stock appreciation rights percentage
Stock awards available for grant
Options outstanding number of shares
Options granted, value
Options outstanding number of value
Stock based compensation expense
Collaborative Arrangement and Arrangement Other than Collaborative [Table]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Payment of severance upon termination
Litigation settlement
Litigation settlement, accrual interest rate
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]
Weighted Average Exercise Price
Market price
Cash commission percentage
Bonus shares percentage
Warrants
Weighted average remaining contractual term
Subsequent Event [Table]
Subsequent Event [Line Items]
Proceeds from issuance of private placement
Commission
General and administrative affiliate.
Interest expense affiliate.
Stock issued during period value conversion between stock classes.
Adjustments to additional paid in capital payroll forfeiture by Mgmnt.
Stock issued during period shares conversion between stock classes.
Stock issued during period value issuance to consultants.
Stock issued during period shares issuance to consultants.
Stock based compensation affiliates.
Increase decrease accounts payable affiliates.
Payroll forgiveness.
Pharmalectin, Inc. [Member]
NDPD Pharma Inc [Member]
Pharmalectin (BVI), Inc. [Member]
Pharmalectin India Pvt Ltd [Member]
Promissory Notes [Member]
Common shares issued for conversion of notes payable and accrued interest.
2021 Note [Member]
Accrued expenses [Policy Text Block]
Warrants [Policy Text Block]
Discount to market price rate.
Working capital.
David Platt [Member]
License amounts.
Affiliate [Member]
Accrued payroll affiliates current.
Accounts payable excluding interest current.
Four Securities Purchase Agreements [Member]
2021 Notes [Member]
Three Notes [Member]
Prepayment percentage.
Note Sold in Exchange for Cash [Member]
Convertible Note And Embedded Derivative [Text Block]
Debt instrument convertible conversion price.
Adjustment multiplier rate.
Volatility impact description.
Concentration risk description.
Allocation of Fair Value Private Placement [Text Block]
Bonus shares.
Schedule of Allocation of Fair Value in Private Placement [Table Text Block]
Fair value of common stock.
Fair value of warrants.
Standalone fair value.
Fair value of common stock percenatge.
Fair value of warrants percenatge.
Percenatge of total fair value.
Allocation calculation description.
Warrant expire date description.
Number of shares issued upon exercise of warrants.
Warrant exercise date.
ShareBased Compensation Arrangement By ShareBased Payment Award NonOption Outstanding Exercise Price Rage Number of Share.
Share based compensation arrangement by share based payment award non option grand in period exercise price.
Share based compensation arrangement by share based payment award non option exercised in period exercise price.
ShareBased Compensation Arrangement by ShareBased Payment Award Non Option Forfeited Or Expired in Period Exercise Price.
Exercise price.
Schedule Of Preferred Stock Issued And Outstanding [Table Text Block]
Preferred Stock Issued and Outstanding [Member]
Stock Conversion [Member]
Payroll Forfeiture [Member]
2021 Stock Plan [Member]
Schedule Of Common Stock Issued And Outstanding [Table Text Block]
Common Stock Issued and Outstanding [Member]
Stock Plan 2021 [Member]
Warrants [Member]
Consulting Fees [Member]
Common Stock Issued [Member]
Commision [Member]
Share based compensation arrangement by share based payment award non options equity instruments outstanding weighted average exercise price.
Share based compensation arrangement by share based payment award non option equity instruments outstanding weighted average remaining contractual term 2 end.
Schedule Of Share Based Payment Award Warrants Valuation Assumptions [Table Text Block]
Share based compensation arrangements by share based payment award non option equity instruments grants in period weighted average exercise price.
Share based compensation arrangements by share based payment award non option equity instruments exercises in period weighted average exercise price.
Share based compensation arrangements by share based payment award non options forfeitures in period weighted average exercise price.
Share based compensation arrangement byshare based payment award non option equity instruments outstanding weighted average remaining contractual term 2.
Share based compensation arrangement byshare based payment award non option equity instruments outstanding weighted average remaining contractual term granted.
Summary Of Warrant Outstanding And Exercisable Warrants [Table Text Block]
Warrant One [Member]
Warrant Two [Member]
Warrant Three [Member]
Share based compensation arrangement by share based payment award non options equity instruments outstanding weighted average exercise price.
Share based compensation arrangement by Share based payment award non options outstanding intrinsic value.
Share based compensation arrangement by share based payment award non options exercisable weighted average remaining contractual term 2.
Stock awards stock appreciation rights percentage.
2021 Stock Plan [Member]
Stipend [Member]
Bonus [Member]
Employment Agreements [Member].
Performance Grant [Member]
Plan 2021 [Member]
Plan 2021 One [Member]
Consulting Fee [Member]
Commission [Member]
Private Placement One [Member]
Consulting Fee One [Member]
Consulting Fee Two [Member]
Cash commission percentage.
Bonus shares percentage.
Cash commission.
Unit Offering [Member]
Short-term loans from affiliates.
Stock issued during period value shares issued under the plan affiliates.
Stock issued during period shares issued under the plan affiliates.
Market Closing of Common Stock [Member]
Weighted average remaining expected term, outstanding.
Weighted average remaining expected term, granted.
2021 Stock Plan [Member] [Default Label]
Assets, Current
Assets
Liabilities, Current
Liabilities
Equity, Attributable to Parent
Liabilities and Equity
Operating Expenses
Operating Income (Loss)
Interest Expense, Nonoperating
InterestExpenseAffiliate
Amortization of Regulatory Asset
Nonoperating Income (Expense)
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest
Net Income (Loss) Attributable to Noncontrolling Interest
Shares, Outstanding
Increase (Decrease) in Prepaid Expense
Increase (Decrease) in Accounts Payable and Accrued Liabilities
Cash Provided by (Used in) Operating Activity, Including Discontinued Operation
Payments to Acquire Intangible Assets
Cash Provided by (Used in) Investing Activity, Including Discontinued Operation
Cash Provided by (Used in) Financing Activity, Including Discontinued Operation
Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Excluding Exchange Rate Effect, Including Discontinued Operation
Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Including Discontinued Operation
Cash and Cash Equivalents, Policy [Policy Text Block]
Cash Equivalents, at Carrying Value
WorkingCapital
Intangible Asset, Finite-Lived, Accumulated Amortization
AccountsPayableExcludingInterestCurrent
Debt Instrument, Interest Rate, Stated Percentage
Debt Instrument, Unamortized Discount
Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number
Shares Outstanding
ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice
ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price